Pathway Choice Focus (NY) 7-Year with ROP review

It depends on your situation. For a New York resident who wants a guaranteed seven-year rate, has no need for a complex crediting menu, and values the return-of-premium feature, this is a straightforward and reasonably competitive product. It is less appealing for someone depositing below $100,000, where the rate gap relative to the upper bands is wide enough to matter over a seven-year horizon. If you are comparing MYGAs nationally, the NY-only restriction removes it from contention entirely.

The main reasons to choose this product are the locked rate, the absence of an MVA, and the built-in ROP rider. A buyer who has experienced rate uncertainty or who wants to avoid the scenario where a market value adjustment turns a modest early surrender into a larger loss will find the combination appealing. The Extended Care waiver — which suspends surrender charges if you need to access funds for qualifying care — is a secondary reason someone nearing or in retirement might find this worth considering over a bare-bones MYGA.

I think this product is best for a New York–based retiree or near-retiree who has a clearly defined seven-year bucket of money, wants a guaranteed rate without any equity exposure or crediting complexity, and values knowing that the ROP rider eliminates the risk of losing principal even in a full surrender. It is also a reasonable fit for a conservative buyer using qualified money in an IRA, since the RMD-friendly structure means distributions do not trigger surrender charges. It is not a good fit for someone who wants growth potential beyond a fixed rate, needs frequent access above 10% per year, or is outside New York.

You are buying a seven-year interest rate guarantee from a New York–regulated insurer. Every dollar you put in earns the declared rate for the full term, with no downside from index performance and no upside beyond that rate. The return-of-premium rider is the product's distinguishing feature — it means the surrender value will never fall below your original premium, even if you surrender in year one and the normal surrender charge would have cut into principal. That is a different promise than a standard MYGA makes. In exchange, you are committing to a seven-year contract where meaningful access beyond 10% annually comes at a cost.

Pathway Choice Focus (NY) 7-Year with ROP credits a fixed declared rate to your account value for the full seven-year surrender period. There are three rate bands: below $100,000, $100,000 to $249,999, and $250,000 and above. As of the brochure date, rates ran 3.35%, 4.15%, and 4.20% respectively, with upcoming rates of 3.45%, 4.25%, and 4.30% for new contracts effective May 2026. The spread between the low band and the top band is nearly a full percentage point, which compounds meaningfully over seven years.

The return-of-premium rider is automatically included with every policy. It guarantees that your surrender value will never fall below your original premium, regardless of when you surrender. That means even if you surrender in year one — when the stated surrender charge is 7% — you still receive at least your full premium back. This is a real and specific guarantee, not a marketing description.

The most meaningful secondary feature is the absence of a market value adjustment. Many MYGAs include an MVA clause that adjusts surrender values up or down based on prevailing interest rates at the time of surrender. In a rising-rate environment, that adjustment typically makes surrendering more expensive than the stated surrender charge alone would suggest. Pathway Choice Focus (NY) does not apply an MVA, which means the surrender charge schedule you see in the contract is the whole story — no interest-rate-dependent surprises on top. Combined with the ROP rider, this makes early surrender more predictable than on competing products that use both charges and MVA.

The free withdrawal provision allows up to 10% of the previous Account Anniversary Value beginning after year one, provided at least $2,000 remains in the account. This is a standard provision for the MYGA category. Withdrawals above the free amount are subject to the following schedule:

No market value adjustment applies on top of these charges, which makes the cost of early exit predictable. The return-of-premium rider ensures that even in year one, a full surrender returns at least the original premium. Required minimum distributions are treated as RMD-friendly, meaning attributable RMDs will not trigger surrender charges — relevant for buyers holding this in a traditional IRA. The Extended Care waiver suspends surrender charges if you enter a qualifying care situation. Terminal illness provisions may also apply. This is a seven-year commitment and should be treated as such, but the liquidity protections here are better than many MYGAs in this duration band.

There are no explicit contract or rider fees on this product. The return-of-premium rider and the Extended Care waiver are included at no additional charge. The cost of these features is embedded in the declared rate — a product with an ROP guarantee and no MVA will generally offer a slightly lower declared rate than a bare-bones competitor without those features. That is an invisible but real tradeoff.

The more visible tradeoff is the rate banding. A buyer at $25,000 earns the low-band rate, which as of the brochure date is roughly 80 basis points below the top tier. Over seven years, that gap has a real compounding effect. It is also worth noting that this is a New York–only product. New York has stricter insurance regulations than most states, and those compliance costs often contribute to slightly less competitive rates compared to the national MYGA market.

Legal Entity: The United States Life Insurance Company in the City of New York

Parent: Corebridge Financial

AM Best Rating: A